Under the leadership of Vasant Narasimhan, the Executive Committee of Novartis (ECN) is responsible for overseeing the business operations of Group companies. ECN members are chosen by the Board of Directors.

Download the Novartis organizational structure (PDF 0.2 MB)

Vasant (Vas) Narasimhan, M.D., Chief Executive Officer
Chief Executive Officer
Vasant (Vas) Narasimhan, M.D.
Shreeram Aradhye, Global Drug Development & Chief Medical Officer
President, Global Drug Development & Chief Medical Officer
Shreeram Aradhye, M.D.
Victor Bulto,  President, Innovative Medicines US
President, Innovative Medicines US
Victor Bulto
Aharon (Ronny) Gal, PhD, Chief Strategy & Growth Officer
Chief Strategy & Growth Officer
Aharon (Ronny) Gal, Ph.D.
Karen L. Hale, Chief Legal Officer
Chief Legal Officer
Karen L. Hale
Harry Kirsch, Chief Financial Officer
Chief Financial Officer
Harry Kirsch
Rob Kowalski, Chief People & Organization Officer
Chief People & Organization Officer
Rob Kowalski
Steffen Lang, Ph.D., President, Operations
President, Operations
Steffen Lang, Ph.D.
Fiona H. Marshall, Ph.D., President, Novartis Institutes for BioMedical Research (NIBR)
President, Novartis Institutes for BioMedical Research (NIBR)
Fiona H. Marshall, Ph.D.
Klaus Moosmayer, Ph.D., Chief Ethics, Risk and Compliance Officer
Chief Ethics, Risk & Compliance Officer
Klaus Moosmayer, Ph.D.
Marie-France Tschudin, President, Innovative Medicines International & Chief Commercial Officer
President, Innovative Medicines International & Chief Commercial Officer
Marie-France Tschudin

Other Members of Senior Management


Lutz Hegemann, M.D., Ph.D., President, Global Health & Sustainability
President, Global Health & Sustainability
Lutz Hegemann, M.D., Ph.D.
Kees Roks, Chief Audit Officer
Chief Audit Officer
Kees Roks
Richard Saynor,  Chief Executive Officer of Sandoz
Chief Executive Officer of Sandoz
Richard Saynor
Michael Willi, Chief Communications Officer
Chief Communications Officer
Michael Willi